Upheaval at the FDA: Leadership Changes Amid Controversy

The U.S. Food and Drug Administration (FDA) is undergoing significant leadership changes, as confirmed by Tracy Beth Hoeg's recent social media post announcing her dismissal as acting head of the drug center. Deputy Michael Davis has taken her place, according to the FDA's website. This change follows the departure of Commissioner Marty Makary, who resigned after facing criticism on drug approval decisions.

The shake-up at the FDA reflects a broader restructuring within the agency, which began during Donald Trump's presidency, leading to numerous firings and resignations. Karim Mikhail has been named acting director of the Center for Biologics Evaluation and Research (CBER), succeeding Vinay Prasad. Furthermore, Lowell Zeta has been appointed acting chief of staff, replacing Jim Traficant.

Tracy Beth Hoeg's tenure at the FDA was marked by controversial decisions, including her initiatives to revise the U.S. childhood vaccination schedule, which was subsequently blocked by a federal court. Under White House directives, Chris Klomp assumed a key role in nominating new candidates for top health positions, reflecting efforts to tighten control over the health agency.

(With inputs from agencies.)